Despite aggressive treatment, the survival rate for high-risk neuroblastoma patients is below 50%. We recently found that these poor-outcome neuroblastomas have a defect in a key drug response pathway, called the JNK pathway. Standard-of-care neuroblastoma drugs all require the JNK pathway to kill neuroblastoma cells, although we have now identified alternative drugs that do not require JNK. We now plan to demonstrate the efficacy of these drugs in neuroblastomas with a defective JNK pathway.
Multidrug Resistance Protein 1 Inhibitors To Sensitise Cancers To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$840,166.00
Summary
Multidrug resistance protein 1 (MRP1) is often present at high levels in cancer cells, where it pumps chemotherapy drugs back out, causing drug resistance. Inhibitors that block MRP1 would increase the effectiveness of chemotherapy. We have developed MRP1 inhibitors with promising activity in cancer cells and mouse tumours and will now develop these inhibitors for clinical application and commercialisation.